

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

CD3 Antibody, anti-human, pure-functional grade

RRID:AB_1036144

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-093-387, RRID:AB_1036144

Antibody Information

URL: http://antibodyregistry.org/AB_1036144

Proper Citation: Miltenyi Biotec Cat# 130-093-387, RRID:AB_1036144

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow Cytometry
Antigen Distribution: NK cells, T cells, thymocytes

Antibody Name: CD3 Antibody, anti-human, pure-functional grade

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: clone OKT3

Antibody ID: AB_1036144

Vendor: Miltenyi Biotec

Catalog Number: 130-093-387

Record Creation Time: 20250820T010525+0000

Record Last Update: 20250820T100015+0000

Ratings and Alerts

No rating or validation information has been found for CD3 Antibody, anti-human, pure-functional grade.

No alerts have been found for CD3 Antibody, anti-human, pure-functional grade.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Bui TM, et al. (2026) Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression. Cancer cell, 44(6), 1179.

Nasi G, et al. (2026) Harnessing skin-resident ?? T cells for immunotherapy in cutaneous squamous cell carcinoma. Science advances, 12(26), eaec7215.

Adabi E, et al. (2025) Enhanced conversion of T cells into CAR T cells by modulation of the MAPK/ERK pathway. Cell reports. Medicine, 6(2), 101970.

Tin E, et al. (2025) SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity. Blood cancer discovery, 6(3), 217.

Lee YJ, et al. (2025) Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. Cell reports. Medicine, 102360.

Hu Y, et al. (2024) Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity. Cell reports. Medicine, 5(5), 101530.

Saggau C, et al. (2024) Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity, 57(10), 2416.

Hu Y, et al. (2024) Protocol for preparing metabolically reprogrammed human CAR T cells and evaluating their in vitro effects. STAR protocols, 5(4), 103333.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell reports. Medicine, 5(3), 101469.

Talbot LJ, et al. (2024) Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(19), 4434.

Ferry GM, et al. (2022) A Simple and Robust Single-Step Method for CAR-V β 1 α T Cell Expansion and Transduction for Cancer Immunotherapy. *Frontiers in immunology*, 13, 863155.

Palmer DC, et al. (2022) Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. *Med (New York, N.Y.)*, 3(10), 682.

Denk D, et al. (2022) Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. *Immunity*, 55(11), 2059.

Geng CL, et al. (2022) Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling. *Cell chemical biology*, 29(8), 1260.

Ma P, et al. (2021) Avidity-Based Selection of Tissue-Specific CAR-T Cells from a Combinatorial Cellular Library of CARs. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 8(6), 2003091.

Seo IH, et al. (2021) IL-15 enhances CCR5-mediated migration of memory CD8⁺ T cells by upregulating CCR5 expression in the absence of TCR stimulation. *Cell reports*, 36(4), 109438.

Liu X, et al. (2021) Distinct human Langerhans cell subsets orchestrate reciprocal functions and require different developmental regulation. *Immunity*, 54(10), 2305.

Sun C, et al. (2020) THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. *Cancer cell*, 37(2), 216.

Yamagishi M, et al. (2019) Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. *Cell reports*, 29(8), 2321.

Bacher P, et al. (2019) Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against *Candida albicans*. *Cell*, 176(6), 1340.